---
company: Alto Ingredients, Inc.
ticker: ALTO
form: 8-K
filed: 2026-05-06
accession: 0001213900-26-052830
source: https://www.sec.gov/Archives/edgar/data/778164/000121390026052830/
---

# Alto Ingredients (ALTO) earnings release, May 6, 2026

Alto Ingredients, Inc. (ALTO) · Form 8-K, Item 2.02 · Filed 2026-05-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/778164/000121390026052830/)

Alto Ingredients, Inc. Reports First Quarter

2026 Results

Q1 2026 Gross Profit of $9.2 Million Increased

$11.0 Million

Q1 2026 Net Income of $4.0 Million, or $0.05 per Share, Improved $16.0 Million

Q1 2026 Adjusted EBITDA of $4.7 Million Improved $9.1 Million Compared to Q1 2025

Pekin, Ill., May 6, 2026 – Alto Ingredients, Inc. (NASDAQ: ALTO), a producer and distributor of renewable fuels, essential ingredients and specialty alcohols, reported its financial results for the quarter ended March 31, 2026.

“In a seasonally weak period for Alto and the industry, we delivered profitability on an adjusted EBITDA and net income basis through the contributions of strong export sales, higher crush margins and incremental earnings from Section 45Z tax credits. Even without the contribution of the tax credits we were profitable,” said President and Chief Executive Officer Bryon McGregor. “Our strategic realignment, combined with our efforts to improve our operational model and the stability of our business have enhanced our earnings power.”

Added Mr. McGregor, “Looking ahead, our priorities are straightforward: improve utilization and reliability; execute our 2026 optimization and capital projects on time and on budget; and leverage the flexibility we have with multiple revenue streams to respond to market shifts and perform profitably through commodity cycles. In addition, we are focused on expanding the value we capture from 45Z tax credits and on optimally monetizing the value of our biogenic CO² production across our facilities to lower our carbon footprint. Through our focus on these priorities, we remain committed to enhancing the value of our assets.”

Financial Results for the Three Months Ended

March 31, 2026 Compared to 2025

Cash and cash equivalents at March 31, 2026 were $20.3 million, compared to $23.4 million at December 31, 2025. The company’s borrowing availability at March 31, 2026 was $94.3 million, including $29.3 million under the company’s operating line of credit and $65 million under its term loan facility.

First Quarter 2026 Results Conference Call

Management will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Wednesday, May 6, 2026, and will deliver prepared remarks via webcast followed by a question-and-answer session.

To receive a number and unique PIN by email, register here. To dial directly up to 20 minutes prior to the scheduled call time, please dial (833) 630-0017 domestically and (412) 317-1806 internationally.

Alternatively, the webcast for the conference call can be accessed from Alto Ingredients’ website at www.altoingredients.com and will be available for one year.

Use of Non-GAAP Measures

Management believes that certain financial measures not in accordance with generally accepted accounting principles ("GAAP") are useful measures of operations. The company defines

Adjusted EBITDA as unaudited consolidated net income (loss) before interest expense, interest income, provision (benefit) for income taxes, asset impairments, unrealized derivative gains and losses, acquisition-related expense, excess insurance proceeds and depreciation and amortization expense. A table is provided at the end of this release that provides a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, net income (loss). Management provides this non-GAAP measure so that investors will have the same financial information that management uses, which may assist investors in properly assessing the company's performance on a period-over-period basis. Adjusted

EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income (loss) or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA has limitations as an analytical tool, and you should not consider this measure in isolation or as a substitute for analysis of the company's results as reported under GAAP.

About Alto Ingredients, Inc.

Alto Ingredients, Inc. (NASDAQ: ALTO) is a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients. Leveraging the unique qualities of its facilities, the company serves customers in a wide range of consumer and commercial products in the Health, Home & Beauty; Food & Beverage;

Industry & Agriculture; Essential Ingredients; and Renewable Fuels markets. For more information, please visit www.altoingredients.com.²

Safe Harbor Statement under the Private

Securities Litigation Reform Act of 1995

Statements and information contained in this communication that refer to or include Alto Ingredients’ estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Alto Ingredients’ current perspective of existing trends and information as of the date of the communication. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,”

“plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,”

“guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,”

“predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning Alto Ingredients’ expectations around profitability and executing on opportunities to grow earnings, including through improved utilization and reliability, optimization and capital projects, monetizing additional Section

45Z tax credits and monetizing the value of its biogenic CO² to lower its carbon footprint; and Alto Ingredients’ other plans, objectives, expectations and intentions. It is important to note that Alto Ingredients’ plans, objectives, expectations and...ntions are not predictions of actual performance. Actual results may differ materially from Alto Ingredients’ current expectations depending upon a number of factors affecting Alto Ingredients’ business and plans. These factors include, among others adverse economic and market conditions, including for renewable fuels, specialty alcohols and essential ingredients; export conditions and international demand for the company’s products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; adverse impacts of inflation and supply chain constraints, including from tariffs; Alto Ingredients’ ability to timely and within budget execute on its optimization and capital projects; Alto Ingredients’ ability to expand and monetize the value of its CO² production to lower its carbon footprint; regulatory developments and Alto Ingredients’ ability to successfully pursue and secure opportunities, and realize the expected results, under existing and new legislation, including the Section

45Z regulations, and to successfully apply for and receive anticipated credit amounts. These factors also include, among others, the inherent uncertainty associated with financial and other projections; the anticipated size of the markets and continued demand for Alto Ingredients’ products; the impact of competitive products and pricing; the risks and uncertainties normally incident to the alcohol production, marketing and distribution industries; changes in generally accepted accounting principles; successful compliance with governmental regulations applicable to Alto Ingredients’ facilities, products and/or businesses; changes in laws, regulations and governmental policies; the loss of key senior management or staff; and other events, factors and risks previously and from time to time disclosed in Alto Ingredients’ filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Alto Ingredients’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13,

2026.

Company IR and Media Contact:

Michael Kramer, Alto Ingredients, Inc., 916-403-2755

Investorrelations@altoingredients.com

IR Agency Contact:

Jody Burfening, Alliance Advisors Investor Relations,

212-838-3777,

Investorrelations@altoingredients.com³

## Financial statements

### Income Statement (Three Months Ended March 31, — (unaudited, in thousands, except per share data))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net sales | 224,680 | 226,540 |
| Cost of goods sold | 215,461 | 228,347 |
| Gross profit (loss) | 9,219 | -1,807 |
| Selling, general and administrative expenses | 6,699 | 7,190 |
| Income (loss) from operations | 2,520 | -8,997 |
| Interest expense, net | -2,198 | -2,729 |
| Transferable tax credits, net | 3,900 |  |
| Other income, net | 49 | 47 |
| Income (loss) before provision for income taxes | 4,271 | -11,679 |
| Net income (loss) | 4,271 | -11,679 |
| Preferred stock dividends | -312 | -312 |
| Net income (loss) attributable to common stockholders | 3,959 | -11,991 |
| Net income (loss) per share, basic | 0.05 | -0.16 |
| Net income (loss) per share, diluted | 0.05 | -0.16 |
| Weighted-average shares outstanding, basic | 74,789 | 73,836 |
| Weighted-average shares outstanding, diluted | 76,639 | 73,836 |

### Income Statement (Three Months Ended March 31, — Reconciliation of Adjusted EBITDA to Net Income (Loss) (in thousands))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Net income (loss) | 4,271 | -11,679 |
| Adjustments: | Interest expense | 2,198 | 2,729 |
| Adjustments: | Interest income | -77 | -84 |
| Adjustments: | Unrealized derivatives gains | -8,073 | -1,634 |
| Adjustments: | Depreciation and amortization expense | 6,366 | 6,266 |
| Adjustments: | Total adjustments | 414 | 7,277 |
| Adjustments: | Adjusted EBITDA | 4,685 | -4,402 |

### Income Statement (Three Months Ended March 31, — Segment Financials (in thousands))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Pekin Campus production: | Alcohol sales | 107,952 | 107,234 |
| Pekin Campus production: | Essential ingredient sales | 43,993 | 44,618 |
| Pekin Campus production: | Intersegment sales | 262 | 297 |
| Pekin Campus production: | Total Pekin Campus sales | 152,207 | 152,149 |
| Marketing and distribution: | Alcohol sales | 47,326 | 49,058 |
| Marketing and distribution: | Intersegment sales | 2,450 | 2,506 |
| Marketing and distribution: | Total marketing and distribution sales | 49,776 | 51,564 |
| Western production: | Alcohol sales | 16,680 | 16,194 |
| Western production: | Essential ingredient sales | 7,280 | 7,808 |
| Western production: | Intersegment sales | 399 | 264 |
| Western production: | Total Western production sales | 24,359 | 24,266 |
| Western production: | Corporate and other | 1,449 | 1,628 |
| Western production: | Intersegment eliminations | -3,111 | -3,067 |
| Western production: | Net sales as reported | 224,680 | 226,540 |
| Cost of goods sold: | Pekin Campus production | 144,021 | 155,222 |
| Cost of goods sold: | Marketing and distribution | 46,037 | 47,650 |
| Cost of goods sold: | Western production | 25,502 | 25,524 |
| Cost of goods sold: | Corporate and other | 1,036 | 1,681 |
| Cost of goods sold: | Intersegment eliminations | -1,135 | -1,730 |
| Cost of goods sold: | Cost of goods sold as reported | 215,461 | 228,347 |
| Gross profit (loss): | Pekin Campus production | 8,186 | -3,073 |
| Gross profit (loss): | Marketing and distribution | 3,739 | 3,914 |
| Gross profit (loss): | Western production | -1,143 | -1,258 |
| Gross profit (loss): | Corporate and other | 413 | -53 |
| Gross profit (loss): | Intersegment eliminations | -1,976 | -1,337 |
| Gross profit (loss): | Gross profit (loss) as reported | 9,219 | -1,807 |

### Balance Sheet (March 31, 2026 — (unaudited, in thousands, except par value))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 20,309 | 23,415 |
| Current Assets: | Restricted cash | 1,334 | 2,258 |
| Current Assets: | Accounts receivable, net | 59,700 | 55,069 |
| Current Assets: | Inventories | 52,831 | 61,676 |
| Current Assets: | Derivative instruments | 7,831 | 525 |
| Current Assets: | Transferable tax credits, net | 11,530 | 7,500 |
| Current Assets: | Other current assets | 5,017 | 5,474 |
| Current Assets: | Total current assets | 158,552 | 155,917 |
| Current Assets: | Property and equipment, net | 193,199 | 198,501 |
| Other Assets: | Right of use operating lease assets, net | 17,215 | 16,931 |
| Other Assets: | Intangible assets, net | 7,419 | 7,574 |
| Other Assets: | Other assets | 9,908 | 9,863 |
| Other Assets: | Total other assets | 34,542 | 34,368 |
| Other Assets: | Total Assets | 386,293 | 388,786 |

### Balance Sheet (LIABILITIES AND STOCKHOLDERS’ EQUITY — (unaudited, in thousands, except par value))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current Liabilities: | Accounts payable | 19,303 | 14,509 |
| Current Liabilities: | Accrued liabilities | 12,332 | 16,691 |
| Current Liabilities: | Current portion – long-term debt |  | 16,600 |
| Current Liabilities: | Current portion – operating leases | 4,975 | 4,958 |
| Current Liabilities: | Derivative instruments | 301 | 1,067 |
| Current Liabilities: | Other current liabilities | 4,741 | 5,246 |
| Current Liabilities: | Total current liabilities | 41,652 | 59,071 |
| Current Liabilities: | Long-term debt | 73,056 | 63,027 |
| Current Liabilities: | Operating leases, net of current portion | 13,240 | 13,012 |
| Current Liabilities: | Other liabilities | 8,467 | 8,435 |
| Current Liabilities: | Total Liabilities | 136,415 | 143,545 |
| Stockholders’ Equity: | Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: no shares issued and outstanding as of March 31, 2026 and December 31, 2025 Series B: 927 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 1 | 1 |
| Stockholders’ Equity: | Common stock, $0.001 par value; 300,000 shares authorized; 77,946 and 77,307 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 78 | 77 |
| Stockholders’ Equity: | Additional paid-in capital | 1,052,472 | 1,051,795 |
| Stockholders’ Equity: | Accumulated other comprehensive income | 5,461 | 5,461 |
| Stockholders’ Equity: | Accumulated deficit | -808,134 | -812,093 |
| Stockholders’ Equity: | Total Stockholders’ Equity | 249,878 | 245,241 |
| Stockholders’ Equity: | Total Liabilities and Stockholders’ Equity | 386,293 | 388,786 |
